StockData
Galectin Therapeutics Inc logo

Galectin Therapeutics Inc (GALT) stock

GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.91−0.11 (-3.64%)

Close on Nov 17, 2026Market cap $293.47MP/E –Yield –

Earnings

Galectin Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 13, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
-$0.14
-$0.12 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Galectin Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 13, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 14, 2026before the open––-$0.14Release
Q1 FY2026ended Mar 31, 2026May 15, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Mar 31, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 14, 2025before the open––-$0.13Release
Q2 FY2025ended Jun 30, 2025Aug 14, 2025before the open––-$0.12Release
Q1 FY2025ended Mar 31, 2025May 15, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Mar 31, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 14, 2024before the open––-$0.18Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024before the open––-$0.20Release
Q1 FY2024ended Mar 31, 2024May 15, 2024before the open––-$0.19Release
Q4 FY2023ended Dec 31, 2023Mar 29, 2024before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Galectin Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Galectin Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Galectin Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Results
  6. Update
  7. Results
  8. Update
  9. Update
  10. Update
  11. Results
  12. Update
  13. Results
  14. Update
  15. Update

See a number that looks wrong?